Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors-Reference-Cited by-同舟云学术

Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors

Published:2014-06 Issue:11 Volume:24 Page:2444-2447
ISSN:0960-894X
Container-title:Bioorganic & Medicinal Chemistry Letters
language:en
Short-container-title:Bioorganic & Medicinal Chemistry Letters

Author:

Rafferty Stephen W.,Eisner Joel R.,Moore William R.,Schotzinger Robert J.,Hoekstra William J.

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry

Reference15 articles.

1. Dreicer, R.; MacLean, D.; Suri, A. et al. Clin. Cancer Res. 2014, in press (epub doi:http://dx.doi.org/10.1158/1078-0432.CCR-13-2436).

2. Abiraterone and Increased Survival in Metastatic Prostate Cancer

3. Schotzinger, R.J.; Degenhardt, T.P.; Wargin, W.A.; Still, J.G.; Gutierrez, M.J. ‘A Phase 1 Multiple-Ascending-Dose Trial of VT-1161, a Highly Potent and Selective Oral Antifungal Agent for the Treatment of Superficial Fungal Infections’. Abstract #7516, Am. Acad. Dermatology Summer Academy Meeting, 2013.

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In silico and in vitro assessment of drugs potentially causing adverse effects by inhibiting CYP17A1;Toxicology and Applied Pharmacology;2024-05

2. Non-steroidal CYP17A1 Inhibitors: Discovery and Assessment;Journal of Medicinal Chemistry;2023-05-16

3. Pre-Clinical and Clinical Evidence of Recent Therapeutic Trends and Spotting Possibility of Cure in Near Future;Therapeutic Drug Targets and Phytomedicine For Triple Negative Breast Cancer;2023-01

4. Anti-Androgenic Therapies Targeting the Luminal Androgen Receptor of a Typical Triple-Negative Breast Cancer;Cancers;2022-12-30

5. Newly Developed Targeted Therapies Against the Androgen Receptor in Triple-Negative Breast Cancer: A Review;Pharmacological Reviews;2022-12-12